Australian ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings

After a snow delay in Washington, Australian-headquartered ChemGenex now has more time to prepare for what will likely be a challenging review of Omapro (omacetaxine mepesuccinate) by U.S. FDA's Oncologic Drugs Advisory Committee